REG - EKF Diagnostics Hldg - Notice of Results & Investor Presentation

EKF Diagnostics HoldingsAnnouncement

14/09/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230914:nRSN3552Ma&default-theme=true

RNS Number : 3552M  EKF Diagnostics Holdings PLC  14 September 2023

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Notice of Interim Results

&

Investor Presentation

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, confirms that the Company will announce its interim results for the
six months ended 30 June 2023 ("H1 2023"), on Tuesday 26 September 2023.

 

Investor Presentation

Julian Baines, Executive Chair, and Steve Young, Chief Financial Officer, will
be hosting a live online presentation relating to the interim results via the
Investor Meet Company platform at 5.30 pm on Tuesday 26 September 2023. The
presentation is open to all existing and potential investors.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:

https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
(https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor)

 

Investors who already follow EKF on the Investor Meet Company platform will
automatically be invited.

 

A recording of the presentation, a PDF of the slides used, and responses to
the Q&A session will be available on the Investor Meet Company platform
afterwards.

 

 

 EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                                Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Broker)                                        Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Oliver Platts

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes,
as well as Central Laboratory products including clinical chemistry reagents,
analysers and centrifuges

 

·    Life Sciences services provide specialist manufacture of enzymes and
custom products for use in diagnostic, food and industrial applications, as
well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUOUSROUUKAAR